Recovery of HPG axis after cessation reported in 20-year cohort study
Pituitary apoplexy management
Biagetti et al. Eur J Endocrinol 2026: updated management recommendations
Hydrocortisone + surgical decompression for moderate-severe cases
Patient Discharge Instructions
copy discharge instructions
Diagnosis and return instructions
You have been evaluated for hypogonadism (low testosterone)
This condition occurs when the body does not produce enough testosterone
You need follow-up blood tests to confirm the diagnosis
Return to the emergency department immediately if you develop
Sudden severe headache, especially with visual changes or double vision
Dizziness, fainting, or inability to stay awake
Persistent vomiting or inability to keep fluids down
Chest pain, shortness of breath, or leg swelling (clot risk)
Sudden scrotal pain or swelling
Worsening confusion or difficulty speaking
Follow-up instructions
Book a fasting morning blood test (drawn between 7-10 AM) within 1-2 weeks
Do not eat before the blood test; blood drawn ideally after a full night's sleep
Follow up with your family doctor or endocrinologist within 2 weeks
Medications and lifestyle
Do not start testosterone replacement without specialist guidance
If you take opioid pain medications, speak to your doctor about their effects on testosterone
Weight loss of even 5-10% of body weight can significantly improve testosterone levels
Alcohol consumption can further lower testosterone — limit intake
If you have been prescribed testosterone therapy
Apply gel to clean dry skin on shoulders or upper arms; avoid genital skin
Wash hands thoroughly after applying; prevent skin-to-skin transfer to others
Do not use testosterone if you are trying to father a child — it prevents sperm production
Blood tests including blood count and PSA will be repeated in 3 months
References
Guidelines and key sources
Primary clinical practice guidelines
Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018
Primary evidence base for TRT initiation, monitoring, and contraindications
De Silva NL et al. Male Hypogonadism: Pathogenesis, Diagnosis, and Management. Lancet Diabetes Endocrinol. 2024
Comprehensive review of HPG axis failure classification
Fleseriu M et al. Hypopituitarism. Lancet. 2024
Panhypopituitarism diagnosis and hormone replacement
Fleseriu M et al. Hormonal Replacement in Hypopituitarism in Adults: Endocrine Society Clinical Practice Guideline. JCEM. 2016
Glucocorticoid and hormone replacement protocols
Iglesias P. Pituitary Apoplexy: An Updated Review. J Clin Med. 2024
Management of acute pituitary hemorrhage/infarction
Biagetti B et al. Update on the Management of Pituitary Apoplexy. Eur J Endocrinol. 2026
Updated surgical and conservative thresholds
Fountas A, Van Uum S, Karavitaki N. Opioid-Induced Endocrinopathies. Lancet Diabetes Endocrinol. 2020
Mechanism and prevalence of opioid HPG suppression
Kanakis GA et al. EMAS Position Statement: Testosterone Replacement Therapy in Older Men. Maturitas. 2023
Risk-benefit framework for TRT in men >=65
Boeri L et al. Testosterone Therapy in Adult Males With Hypogonadism. Eur Urol. 2025
Monitoring protocols and structured follow-up
Bhasin S, Snyder PJ. Testosterone Treatment in Middle-Aged and Older Men. NEJM. 2025
TRAVERSE trial data on cardiovascular safety
Lee H et al. Testosterone Replacement in Men With Sexual Dysfunction. Cochrane Database Syst Rev. 2024
Efficacy of TRT for erectile and sexual function
Basaria S. Male Hypogonadism. Lancet. 2014
Foundational epidemiology and classification
Husebye ES et al. Adrenal Insufficiency. Lancet. 2021
Adrenal crisis diagnosis and management
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.